Skip to main content

Table 5 Spearman rank correlation of change in ESR1 expression/pre-selected gene signature scores and percentage of 2-week change in Ki67/residual Ki67 level in (i) HER2− tumours, (ii) HER2+ tumours, and (iii) significance of the difference between the two correlation coefficients (HER2− vs HER2+).

From: Impact of aromatase inhibitor treatment on global gene expression and its association with antiproliferative response in ER+ breast cancer in postmenopausal patients

Change in gene signature scoresHER2− (n = 135)HER2+ (n = 22)Significance of the difference between two correlation coefficients (HER2− vs HER2+)
Change in Ki67 (n = 121)Residual Ki67 (n = 124)Change in Ki67 (n = 21)Residual Ki67 (n = 22)
Signature nameReferenceRhop valueRhop valueRhop valueRhop valueChange in Ki67Residual Ki67
ESR1 − 0.083.58E−010.037.37E−010.416.70E−020.482.20E−023.69E−024.61E−02
E2F4activation-GSGuerrero-Zotano et al.0.382.12E−050.131.58E−010.425.84E−020.184.22E−018.47E−018.36E−01
DiLeoRBloss-GSMalorni et al.0.364.29E−050.093.12E−010.407.55E−020.232.94E−018.50E−015.60E−01
JClinInvest2007RBloss-GSBosco et al.0.351.05E−040.083.87E−010.388.53E−020.223.31E−018.89E−015.62E−01
GGI-GSSotiriou et al.0.341.30E−040.083.75E−010.416.28E−020.242.77E−017.42E−015.05E−01
CIN70-GSCarter et al.0.332.16E−040.093.26E−010.435.18E−020.233.04E−016.36E−015.60E−01
E2FmotifCellCycleAssociated-GSMiller et al.0.314.37E−040.046.91E−010.531.38E−020.096.84E−012.75E−018.39E−01
Gene70-GSvan ‘t Veer et al.0.315.01E−040.055.90E−010.444.65E−020.145.46E−015.39E−017.13E−01
E2Factivation-GSMiller et al.0.291.49E−030.131.40E−010.425.92E−020.048.59E−015.46E−017.14E−01
ERGs-GSDunbier et al.0.255.44E−030.281.96E−030.116.30E−010.492.07E−025.58E−013.15E−01
PTEN-GSSaale at al.0.231.16E−020.046.24E−010.463.43E−020.203.79E−012.87E−015.10E−01
PI3K-GSCreighton 20100.231.31E−020.121.95E−010.501.99E−020.379.24E−022.02E−012.79E−01
AURKA-GSDesmedt et al.0.212.32E−020.018.70E−010.463.37E−020.387.72E−022.50E−011.15E−01
E2F3-GSBild et al.0.203.20E−020.074.34E−010.435.18E−020.331.36E−012.98E−012.70E−01
WntTarget34-GSVerhaeghCR2014TableS10.176.11E−020.166.99E−020.116.26E−01− 0.096.91E−018.04E−013.09E−01
AKT/mTOR-GSMajumder et al.0.159.44E−020.141.20E−010.292.03E−010.252.64E−015.51E−016.43E−01
IGF1-GSCreighton et al.0.131.61E−01− 0.055.80E−010.321.54E−010.425.41E−024.16E−014.41E−02
ERTarget27-GSVerhaeghCR2014TableS20.121.86E−010.193.26E−020.291.97E−010.415.85E−024.72E−013.25E−01
MacTh1-GSIglesia et al.0.102.57E−010.093.23E−01− 0.174.51E−01− 0.145.33E−012.71E−013.50E−01
CASP3-GSDesmedt et al.0.093.06E−010.122.00E−010.174.64E−01− 0.087.32E−017.42E−014.17E−01
STAT1-GSDesmedt et al.0.074.50E−010.028.06E−010.116.30E−01− 0.223.18E−018.70E−013.24E−01
GDNF-GSMorandi et al.0.064.80E−010.046.99E−010.203.94E−010.038.91E−015.64E−019.68E−01
MYC-GSBild et al.0.065.30E−01− 0.102.60E−010.407.14E−020.434.41E−021.41E−012.34E−02
Inflammatory-GSDunbier et al.0.065.34E−010.037.56E−01− 0.193.97E−01− 0.282.04E−013.07E−011.99E−01
Bcell-GSIglesia et al.0.055.55E−010.027.97E−01− 0.019.55E−01− 0.549.42E−038.08E−011.16E−02
Tcell-GSIglesia et al.0.055.61E−01− 0.028.09E−01− 0.416.46E−02− 0.331.36E−014.95E−021.92E−01
obesity-GSCreighton et al.0.055.67E−01− 0.121.91E−01− 0.223.33E−010.233.06E−012.68E−011.51E−01
VEGF-GSDesmedt et al.0.037.41E−01− 0.028.34E−010.463.43E−020.631.57E−035.87E−022.07E−03
Stroma.2.PLAU-GSDesmedt et al.0.028.14E−010.019.55E−01− 0.213.51E−01− 0.174.46E−013.46E−014.62E−01
BetaCatenin-GSBild et al.0.028.50E−01− 0.074.09E−01− 0.029.29E−010.331.39E−018.71E−019.48E−02
Stroma.1-GSFarmer at al.0.009.71E−010.046.27E−01− 0.203.88E−01− 0.262.51E−014.12E−012.16E−01
MAPK-GSCreighton et al.− 0.019.24E−01− 0.074.24E−01− 0.272.36E−01− 0.301.70E−012.80E−013.33E−01
Immune.1-GSTeschendorff at al.− 0.019.12E−01− 0.037.16E−01− 0.164.78E−010.038.79E−015.40E−018.08E−01
PIK3CA-GSLoi et al.− 0.019.00E−010.028.03E−01− 0.233.22E−01− 0.155.13E−013.64E−014.89E−01
SRC-GSBild et al.− 0.037.43E−01− 0.131.58E−01− 0.067.97E−01− 0.145.46E−019.03E−019.67E−01
ESR1.1-GSMackay et al.− 0.056.16E−010.074.16E−010.311.71E−010.424.99E−021.34E−011.27E−01
SET-GSSymmans et al− 0.055.70E−010.093.21E−010.223.28E−010.453.36E−022.68E−011.11E−01
RAS-GSBild et al.− 0.064.99E−01− 0.131.39E−010.407.44E−020.116.29E−015.04E−023.29E−01
ESR1.2-GSDesmedt et al.− 0.102.81E−010.055.69E−010.291.97E−010.622.21E−031.07E−016.32E−03
ERBB2-GSDesmedt et al.− 0.249.08E−03− 0.221.20E−02− 0.048.80E−010.155.06E−014.08E−011.29E−01
TP53-GSCoutant et al.− 0.372.38E−05− 0.121.82E−01− 0.321.63E−01− 0.321.43E−018.18E−013.93E−01
PAGsGao et al.0.273.11E−030.074.68E−010.472.99E−020.116.12E−013.45E−018.70E−01
  1. Change in TP53-GS score was the strongest inversely associated with the change in Ki67 after 2-week AI treatment. The inverse correlation relates to the increase of TP53-GS score being associated positively with TP53 wild-type status